Source: Medical Prognosis Institute
Hoersholm, Denmark, May 17th, 2017 - Medical Prognosis Institute A/S ("MPI") today announced that the previously warranted abstract with DRP data on epirubicin for breast cancer has been published electronically on the website of ASCO (American Society of Clinical Oncology). The title of the abstract is "Retrospective-prospective blinded evaluation predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort". The DRP was significantly associated to Progression Free Survival (PFS) in a cohort of 137 metastatic breast cancer patients. PFS is a measure of the total time epirubicin can block tumor growth. The estimated median time to progression for a patient with a DRP value of 25% was 7 months versus 13 months for a patient with a DRP value of 75%. The result is of tremendous value to MPI as epirubicin response prediction is an important part of building a broader Patient Response Prediction (PRP(TM)) Compass for individual patients and also for Oncology Ventures spinout 2X Oncology Inc. in developing the GSH-liposomal- doxorubicin for breast and brain cancer with their in-licensed product 2X-111. MPI will own 10% of 2X Oncology Inc. after a successful series A financing.
The poster including update of data will be presented on the 4th of June 2017 at the annual ASCO conference in Chicago, USA taking place from June 2-6 2017.
Epirubicin - which is an anthracycline like doxorubicin - is a cornerstone in the treatment of primary and advanced breast cancer. Usually about 50% will benefit with a reduction in their tumor size. Until now there has been no method to find out who will benefit and who will not. The current study looked at 137 epirubicin treated patients to evaluate MPI's Epirubicin Drug Response Predictor (DRP(TM)). The DRP was significantly associated to Progression Free Survival (PFS) that measures the total time epirubicin can block tumor growth. The estimated median time to progression for a patient with a DRP value of 25% was 7 months versus 13 months for a patient with a DRP value of 75%.
The result is of tremendous value to MPI as epirubicin response prediction is an important part of building a broader Patient Response Prediction (PRP(TM)) Compass for individual patients and also for Oncology Ventures spinout 2X Oncology Inc. in developing the GSH-liposomal- doxorubicin for breast and brain cancer with their in-licensed product 2X-111. MPI will own 10% of 2X Oncology Inc. after a successful series A financing.
"These data are of great importance to MPI as our patented Epirubicin DRP(TM) is now with statistically significance validated also in clinical practice. 2X Oncology Inc.'s product 2X-111 is very similar to epirubicin- and I am confident that by using the DRP(TM) to analyze the individual patient's tumor we can find those patients who are most likely to benefit from 2X-111. Anthracyclines are cornerstone products for treating breast cancer patients all over the world. Further to this the new published data strengthen MPI's Personalized Response Predictor - an oncology drug compass for the individual patient.", said Adjunct Professor Peter Buhl Jensen, M.D., CEO of MPI. "MPI will own 10% of 2X Oncology Inc. after a successful series A financing," Peter Buhl Jensen further commented.
Earlier this year (24th of January 2017) Medical Prognosis Institute and Oncology Venture published information on data based on more than 800 patients with metastatic breast cancer that demonstrated with statistical significant values that the Patient Response Predictor (PRP) could predict whether the individual patients would respond on the treatment with epirubicin (an anthracycline like doxorubicin), fulvestrant, anastrazole and exemestan or not. As there is a high number of active anticancer agents for Breast Cancer and this approach has been very fruitful, MPI and Oncology Venture will continue to broaden the database and the data mining to increase the number of products where our DRP technology can bring value to the choice of therapy.
The abstract will be released by ASCO
on May 17, 2017, at 5:00 PM EDT/23:00 CET on abstracts.asco.org
An up-date on data from the abstract will be presented as a poster on the poster session Breast Cancer-Metastatic
on the 4th of June 2017 at 8:00 AM-11:30 AM local time/15:00-18:30 CET.
ASCO, American Society of Clinical Oncology, ANNUAL MEETING. McCormick Place, Chicago, Illinois, USA.
Founded in 1964, the American Society of Clinical Oncology (ASCO) is committed to making a world of difference in cancer care. As the world's leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. The ASCO Annual Meeting is considered the premiere international forum for the presentation of scientific research and state-of-the-art education in clinical oncology. The five-day event attracts 30,000 attendees from around the world. Clinical trial results and updates presented at ASCO's Annual Meeting represent the significant progress made each year in the fight against cancer.
For further information on Oncology Venture please contact
| Ulla Hald Buhl, COO and |
Chief IR & Communications
Mobile: +45 2170 1049
| or|| Peter Buhl Jensen, CEO|
Mobile: +45 21 60 89 22
This information is that Oncology Venture Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on May 17th 2017.
About the DRP(TM) Companion Diagnostic
Developed by and in-licensed from Medical Prognosis Institute, the DRP(TM) screening platform utilizes messenger RNA (mRNA) gene expression signatures from patient biopsies to identify patients with a high likelihood of responding to specific cancer-fighting therapies. This DRP(TM) method builds on the comparison of sensitive vs. resistant human cancer cell lines, including genomic information from cell lines, combined with clinical tumor biology and clinical correlates in a systems biology network. Specific DRP(TM)'s are developed for each pipeline product, which will enable us to identify and predict which patients are most likely to respond and thereby benefit from a given pipeline product. This would enable likely responders to receive appropriate treatment while expediting the decision path for predicted non-responders, saving them critical time and money in their cancer fight.
About Oncology Venture Sweden AB (OV)
OV is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction - DRP(TM) - in order to significantly increase the probability of success in clinical trials. DRP(TM) has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients' tumors genes are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.
The current product portfolio: LiPlaCis for Breast Cancer in collaboration with Cadila Pharmaceuticals, Irofulven developed from a fungus for prostate cancer and APO010 - an immuno-oncology product for Multiple Myeloma.
Oncology Venture has spun out 2X Oncology Inc. a company focused on developing precision medicine for women's cancer with three anticancer products in pipeline and OV-SPV2 which will test and potentially develop an oral Tyrosine Kinase inhibitor from a Big Pharma the treatment of cancers.
About MPI's multiple biomarker called Drug Response Predictor - DRP(TM)
MPI's DRP(TM) is a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The DRP(TM) has been tested in 37 trials, where 29 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients responded well to the treatment. The DRP(TM) platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anti-cancer drug. In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRP(TM) builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP(TM) is a Big Data tool based on messenger RNA.
The DRP(TM) platform can be used in all cancer types, and has been patented for more than 60 anti-cancer drugs in the US.
Medical Prognosis is a publicly traded international company specialized in improving cancer patients lives by developing Personalized Medicine using its unique DRP(TM) technology. MPI's exceptional opportunity to personalize cancer treatment - begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI's DRP(TM) tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,100 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark.
For further information, please contact:
CEO, Peter Buhl Jensen, Adjunct Professor, MD, PhD Ulla Hald Buhl, IR & Communication
E-mail: email@example.com E-mail: firstname.lastname@example.org
Telephone: +45 21 60 89 22 Telephone +45 21 70 10 49
This information is information that Medical Prognosis Institute A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on May 17th 2017.
Certified Advisor: Sedermera Fondkommission, Norra Vallgatan 64, 211 22, Malmö, Sweden